Following Lipectomy to Understand Adipose Tissue Re-accumulation (FLARE)

January 10, 2017 updated by: University of Colorado, Denver

Regional Fat Re-accumulation Following Lipectomy in Pre- and Post-menopausal Women

The typical female pattern of accumulating fat in the hips and thighs has long been thought to confer less risk for disease than the typical male abdominal fat pattern. However, leg fat may not simply be benign with respect to disease risk, but may in fact protect against cardiovascular disease risk. Although the mechanism for this is unknown, the investigators hypothesize that removing a portion of this important fat depot (via liposuction) could increase disease risk. Such unfavorable results may or may not be transient depending on an individual's ability to defend their fat mass. Because sex hormones appear to play a role in regional fat accumulation, the investigators hypothesize that estrogen-deficient postmenopausal women may have an augmented abdominal fat accumulation and an attenuated hip and thigh re-accumulation compared to premenopausal women following lipectomy and compared to non-surgical controls. As a result, the increased abdominal fat accumulation may worsen disease risk in postmenopausal women. Menopause-related differences in fat storage at baseline are also expected to determine the degree to which lipectomy alters disease risk and the propensity for AT re-accumulation.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Lipectomy is the most frequently performed aesthetic surgery in the U.S. today and is considered permanent, by The American Society for Aesthetic Plastic Surgery, but no long term follow-up studies have been done to verify this assertion. Indeed, animal studies suggest rapid adipose tissue (AT) re-accumulation after lipectomy is common and may even be accompanied by unfavorable changes in disease risk. Recent studies in humans have focused on abdominal lipectomy as a means of reducing metabolic disease risk in obese premenopausal women. However, none of these studies evaluated AT re-accumulation or reported long-term (>6 mo) changes in metabolic outcomes, and none have evaluated the effect of removing femoral AT despite this being a common site for lipectomy in women and despite the apparent cardioprotective benefit of lower body adiposity. Further, none of these studies included postmenopausal women who are at an increased risk of abdominal AT accumulation. It is the investigator's overall working hypothesis that removal of femoral AT by lipectomy may worsen metabolic disease risk (as measured by postprandial lipemia) in estrogen-deficient postmenopausal women who, in contrast to premenopausal women, will accumulate AT in the abdominal rather than the femoral region. The global aims of this study are to determine whether: 1) there are menopause-related differences in regional (abdominal vs. femoral) AT re-accumulation following lipectomy; and 2) changes (removal and regain) in femoral AT mass alter postprandial triglyceride clearance and storage of meal-derived fatty acids. Further, the investigators postulate that menopause-related differences in postprandial lipemia and handling of dietary fatty acids will determine the degree to which femoral lipectomy worsens these parameters. Pre- and postmenopausal women (n=80) will be randomly assigned to either femoral lipectomy or control (no surgery). All eligible volunteers will undergo testing at the beginning of the study and at 2, 8, and 14 months following lipectomy. Measurements will include body composition assessments, meal tests and AT biopsies to assess lipectomy-related changes in: 1) abdominal and femoral fat mass; 2) systemic postprandial triglyceride excursions; and 3) storage of dietary fatty acids in AT. These studies are designed to evaluate the effect of femoral lipectomy on regional AT re-accumulation and metabolic disease risk in pre- and postmenopausal women.

Study Type

Interventional

Enrollment (Actual)

53

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Aurora, Colorado, United States, 80045
        • University of Colorado Anschutz Medical Campus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • post-menopausal (no menses for 12mo or oophorectomy w/ follicle-stimulating hormone (FSH)>30 IU/L) OR- pre-menopausal (regular menses 28+/-3d)
  • BMI >20 and <30 kg/m2)
  • weight stable (+/- 2kg in past 2mo)
  • non-smoking
  • no use of hormone therapies or oral contraceptives
  • actively seeking liposuction of the hips and thighs
  • good femoral lipectomy candidates as determined by cosmetic surgeon

Exclusion Criteria:

  • severe hypertriglyceridemia (>400 mg/dL)
  • medications known to affect lipid metabolism
  • elevated resting blood pressure (Systolic >140 mm Hg,Diastolic >90 mm Hg)
  • history of lipectomy or gastric bypass surgery
  • body dysmorphic disorder
  • pregnant, lactating or intention of becoming pregnant
  • indication of high surgical risk (e.g., abnormal resting ECG, history of thromboembolism, valvular heart disease)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Premenopausal, Control
Premenopausal women randomized to Control (delayed liposuction surgery)
Active Comparator: Premenopausal, Surgery
Premenopausal women randomized to surgery (femoral lipectomy)
Standard (non-experimental) suction assisted liposuction surgery
No Intervention: Postmenopausal, Control
Postmenopausal women randomized to Control (delayed liposuction surgery)
Active Comparator: Postmenopausal, Surgery
Postmenopausal women randomized to surgery (femoral lipectomy)
Standard (non-experimental) suction assisted liposuction surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Postprandial triglyceride excursions (incremental areas)
Time Frame: Baseline, 2Mo, and 14Mo
Baseline, 2Mo, and 14Mo
Abdominal and femoral fat mass accumulation
Time Frame: Baseline, 2Mo, and 14Mo
Baseline, 2Mo, and 14Mo

Secondary Outcome Measures

Outcome Measure
Time Frame
Triglyceride storage (14C-oleic acid incorporation into abdominal and femoral adipose tissue)
Time Frame: Baseline, 2Mo, and 14Mo
Baseline, 2Mo, and 14Mo
Lipoprotein lipase activity (abdominal and femoral adipose tissue)
Time Frame: Baseline, 2Mo, and 14Mo
Baseline, 2Mo, and 14Mo

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

October 12, 2009

First Submitted That Met QC Criteria

October 13, 2009

First Posted (Estimate)

October 15, 2009

Study Record Updates

Last Update Posted (Estimate)

January 11, 2017

Last Update Submitted That Met QC Criteria

January 10, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 07-0339
  • NIH DK077992

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe